Quest Diagnostics INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NYSE
T. Rowe Price Associates, Inc. has filed a Schedule 13G, disclosing a beneficial ownership of 5,428,244 shares, representing 4.9% of Quest Diagnostics Inc.'s common stock.
NYSE
Vanguard Capital Management has reported beneficial ownership of 8,274,567 shares, representing 7.53% of Quest Diagnostics Inc.'s common stock as of March 31, 2026.
NYSE
Vanguard Portfolio Management has reported a beneficial ownership of 5.54% in Quest Diagnostics Inc. common stock as of March 31, 2026.
NYSE
The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Quest Diagnostics Inc. following an internal realignment.
NYSE
SCHEDULE 13G/A: T. Rowe Price Discloses 6.5% Stake in Quest Diagnostics
T. Rowe Price Associates, Inc. has reported a 6.5% beneficial ownership stake in Quest Diagnostics Inc. as of June 30, 2025.
NYSE
T. Rowe Price Associates, Inc. has filed a Schedule 13G, revealing a beneficial ownership of 5.4% of Quest Diagnostics Inc.'s common stock as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 8.4% Passive Stake in Quest Diagnostics
BlackRock, Inc. has filed an amended Schedule 13G, revealing a passive beneficial ownership of 8.4% of Quest Diagnostics Inc.'s common stock as of March 31, 2025.